Memantine is a selective blocker of N-methyl-D-aspartate (NMDA) — glutamate receptors. The mechanism of action is associated with modulation of the glutamatergic transmission, which, mediates cortico-cortical and cortico-subcortical interrelations in the brain. In a series of controlled studies demonstrated the ability of Memantine to improve and stabilize cognitive function, daily activity, reduce behavioral disorders in patients with BA (as at an early stage, and especially at the stage of moderate and severe dementia).
Positive effect of Memantine on cognitive function was observed in vascular dementia. In open studies have shown the effectiveness of Memantine mixed dementia, dementia with Lewy body, alcoholic dementia and Korsakoff's amnesic syndrome, frontotemporal dementia. Memantine — a drug of first choice in moderate and severe dementia, but can also be used at the stage of mild dementia as monotherapy or in combination with cholinesterase inhibitors. Long-term effectiveness of Memantine have been less studied.
For Memantine characterized by good tolerability, however, phase titration may experience dizziness or confusion, which usually are transient in nature. Less marked drowsiness, and headache. In the experiment it was shown that Memantine is able to protect cells from the toxic effects of excitatory amino acids and inhibit the formation of neurofibrillary glomeruli, affecting the metabolism of t-protein, which is one of the key elements of the pathogenesis of BA.Rate Memantine
the Dosage is from 20 to 80 mg per day. On prescription, increased to 100 mg. the duration of the course is determined by a physician and an average of 1 month.